Get the Stockscreener App
4.195
2.18%
0.075
Sight Sciences Inc stock is traded at $4.195, with a volume of 7,905.
It is up +2.18% in the last 24 hours and up +23.46% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$4.12
Open:
$4.15
24h Volume:
7,905
Relative Volume:
0.05
Market Cap:
$216.60M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-3.6798
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
+20.63%
1M Performance:
+23.46%
6M Performance:
+64.45%
1Y Performance:
-27.29%
1-Day Range:
$4.10
$4.20
1-Week Range:
$3.41
$4.27
52-Week Range:
$2.03
$7.05
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
4.19 | 219.22M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
130.13 | 233.71B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.47 | 152.83B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.03 | 144.35B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.36 | 119.00B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.43 | 46.00B | 5.69B | 4.14B | 577.90M | 6.96 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-25 | Upgrade | Lake Street | Hold → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Will Sight Sciences Inc. see short term momentumSafe Investment Ideas with Growth Upside - Newser
Analyzing Sight Sciences Inc. with risk reward ratio chartsFree Community Shared Smart Money Signals - Newser
Will Sight Sciences Inc. price bounce be sustainableFree AI Driven Buy Alert Trade Blueprint - Newser
Sight Sciences, Inc. (NASDAQ:SGHT) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Raised to Hold at Wall Street Zen - Defense World
Will earnings trigger a reversal in Sight Sciences Inc.Free Conservative Long Term Growth Plans - Newser
Chart based exit strategy for Sight Sciences Inc.Free Price Action Based Buy Opportunity List - Newser
Real time breakdown of Sight Sciences Inc. stock performanceFree Intraday Trend Analysis for Fast Gains - Newser
Risk adjusted return profile for Sight Sciences Inc. analyzedPrice Action Trading with Volume Confirmation - Newser
Sight Sciences, Inc. (NASDAQ:SGHT) Q2 2025 Earnings Call Transcript - MSN
Sector Leaders Rotate Capital Into Sight Sciences Inc.Community Shared Smart Money Signals Show Movement - metal.it
Sight Sciences raises 2025 revenue guidance to $72M–$76M amid strong OMNI growth and strategic focus on MIGS leadership - MSN
Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics - MSN
Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet? - simplywall.st
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $4 to $5 - 富途牛牛
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Sight Sciences Reports Q2 EPS, Revenue Above Consensus, Glaucoma Ordering Accounts Reach New High - AInvest
Sight Sciences stock rating upgraded by Lake Street on stabilizing business - Investing.com Australia
Sight Sciences' Q2 2025: Navigating Contradictions in TearCare Reimbursement and Market Dynamics - AInvest
Sight Sciences Boosts 2025 Revenue Guidance to $72M-$76M on OMNI Growth and MIGS Leadership Focus - AInvest
Earnings call transcript: Sight Sciences Q2 2025 beats revenue expectations By Investing.com - Investing.com Nigeria
Earnings call transcript: Sight Sciences Q2 2025 beats revenue expectations - Investing.com
Sight Sciences August 2025 slides: Targeting growth in $9B eye care market despite Q1 headwinds - Investing.com Australia
Sight Sciences 2025 Q2 Earnings Slight Improvement in Losses Amid Revenue Decline - AInvest
Sight Sciences Reports Q2 2025 Financial Results - TipRanks
Sight Sciences Lifts Outlook Despite Revenue Slump - Finimize
Sight Sciences Releases Second Quarter Results and Raises Full-Year Guidance - VisionMonday.com
Sight Sciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Sight Sciences, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Sight Sciences reports Q2 EPS (23c), consensus (28c) - TipRanks
Sight Sciences: Navigating Revenue Headwinds and Regulatory Challenges to Secure Long-Term Growth - AInvest
Sight Sciences: A Resilient Earnings Beat Signals Undervaluation and Growth in Ophthalmic Innovation - AInvest
Sight Sciences Raises Full-Year Revenue Guidance - TipRanks
Sight Sciences earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - GlobeNewswire
SAHARA trial demonstrates sustained TearCare benefits for evaporative DED - Ophthalmology Times
Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye - Optometry Times
Strategies to average down on Sight Sciences Inc.Day Trading Setup Forecast with Trend Model - Newser
Sight Sciences (SGHT) to Release Quarterly Earnings on Thursday - Defense World
What high frequency data says about Sight Sciences Inc.Equity Signal Recap With Long-Term Summary - Newser
What makes Sight Sciences Inc. stock price move sharplyFree Fundamental Growth Stock Analysis - Newser
Will Sight Sciences Inc. outperform the marketFree Community Verified Stock Suggestions - Newser
Is Sight Sciences Inc. Stock a Good Fit for Conservative InvestorsConsistent Gain Plan with AI Support - Newser
Is Sight Sciences Inc. a good long term investmentInvest smarter with expert stock recommendations - Jammu Links News
What are analysts’ price targets for Sight Sciences Inc. in the next 12 monthsGet daily expert analysis for smarter investing - Jammu Links News
What is Sight Sciences Inc. company’s growth strategyAccelerated investment success - Jammu Links News
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sight Sciences Inc Stock (SGHT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HAYDEN JEREMY B. | Chief Legal Officer |
Jul 03 '25 |
Sale |
4.17 |
9,160 |
38,234 |
266,321 |
| Bauerlein Alison | Chief Financial Officer |
Jul 02 '25 |
Sale |
4.10 |
19,260 |
78,927 |
617,468 |
| Badawi Paul | President and CEO |
Jul 01 '25 |
Sale |
4.15 |
23,637 |
98,141 |
5,986,943 |
| Badawi David | Chief Technology Officer |
Jul 03 '25 |
Sale |
4.17 |
5,679 |
23,704 |
1,831,025 |
| Link Matthew | Chief Commercial Officer |
Jul 02 '25 |
Sale |
4.10 |
4,889 |
20,035 |
832,293 |
0.30%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):